Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC

Simple item page
dc.contributor.authorMok, T.
dc.contributor.authorNakagawa, K.
dc.contributor.authorRosell, R.
dc.contributor.authorLee, K.
dc.contributor.authorCorral, J.
dc.contributor.authorMigliorino, M. R.
dc.contributor.authorPluzanski, A.
dc.contributor.authorLinke, R.
dc.contributor.authorDevgan, G.
dc.contributor.authorSbar, E.
dc.contributor.authorQuinn, S.
dc.contributor.authorWang, T.
dc.contributor.authorWu, Y.
dc.contributor.authoraffiliation[Mok, T.] Chinese Univ Hong Kong, Hong Kong, Peoples R China
dc.contributor.authoraffiliation[Nakagawa, K.] Kindai Univ Hosp, Osaka, Japan
dc.contributor.authoraffiliation[Rosell, R.] Catalan Inst Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Lee, K.] Chungbuk Natl Univ Hosp, Cheongju, South Korea
dc.contributor.authoraffiliation[Corral, J.] Hosp Univ Virgen Del Rocio, Seville, Spain
dc.contributor.authoraffiliation[Migliorino, M. R.] San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy
dc.contributor.authoraffiliation[Pluzanski, A.] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland
dc.contributor.authoraffiliation[Linke, R.] Sfj Pharmaceut Grp, Pleasanton, CA USA
dc.contributor.authoraffiliation[Devgan, G.] Pfizer Oncol, New York, NY USA
dc.contributor.authoraffiliation[Sbar, E.] Pfizer Oncol, Collegeville, PA USA
dc.contributor.authoraffiliation[Quinn, S.] Pfizer Oncol, Cambridge, MA USA
dc.contributor.authoraffiliation[Wang, T.] Pfizer Oncol, Cambridge, MA USA
dc.contributor.authoraffiliation[Wu, Y.] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
dc.contributor.authoraffiliation[Wu, Y.] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
dc.date.accessioned2025-01-07T15:34:26Z
dc.date.available2025-01-07T15:34:26Z
dc.date.issued2018-10-01
dc.identifier.doi10.1016/j.jtho.2018.08.546
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086418315041/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27249
dc.identifier.wosID454014501181
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS454-S454
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectdose reduction
dc.subjectnon-small cell lung cancer
dc.subjectDacomitinib
dc.titleEffects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía